This says it all ...
"Revenue was approximately $40,000 and $64,000 during the three months ended January 31, 2013 and 2012, respectively. The decrease in revenue of approximately $24,000 resulted primarily from a decrease in revenues from of our ValiMed maintenance fees."
"The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have experienced net losses since our inception and, as of January 31, 2013, had an accumulated deficit of approximately $34 million. We do not expect to have positive cash flow from operations until we have deployed a sufficient number of our ValiMed G4 drug validation systems."
"We had a net decrease in cash of approximately $122,000 during the three months ended January 31, 2013. During the first three months of fiscal 2013, we used $122,000 of cash in operating activities. This amount is comprised primarily of our net loss of $562,000 partially and an increase in inventory of $72,000, offset by a non-cash share-based compensation expense of $342,000 and an increase in our current liabilities of $151,000."
From $2150 a share (reverse split adjusted) in September of 2000... down to 6 cents a share today.
Several failed Billion Dollar Techs ... Several turnovers in CEOs and Biard Members.
Investors have done nothing but Lise money in over 12 years.
Insiders making millions of dollars over the last decade plus.
...and it continues. ...
~Kidd
~Ouch
~Out
AI
